What is the address of DR. MED. SPIESSENS THOMAS?

The registered office of DR. MED. SPIESSENS THOMAS is located at Dennenlaan 46, 2243 Zandhoven.

Is DR. MED. SPIESSENS THOMAS still active?

Yes. According to the CBE (16 September 2026) DR. MED. SPIESSENS THOMAS is active, legal situation “Normale toestand”, started on 26 October 2000.

Is DR. MED. SPIESSENS THOMAS registered on Peppol?

No, DR. MED. SPIESSENS THOMAS is currently not registered on the Peppol network.

What is the enterprise number of DR. MED. SPIESSENS THOMAS?

The enterprise number of DR. MED. SPIESSENS THOMAS is BE0473128386.

When was DR. MED. SPIESSENS THOMAS founded?

DR. MED. SPIESSENS THOMAS was founded on 26 October 2000.

Who are the directors of DR. MED. SPIESSENS THOMAS?

According to the 2025 annual accounts, the directors of DR. MED. SPIESSENS THOMAS are: Thomas Spiessens.

Is DR. MED. SPIESSENS THOMAS a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 26 October 2000; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did DR. MED. SPIESSENS THOMAS make in 2025?

DR. MED. SPIESSENS THOMAS posted a profit after taxes of € 102,208 in financial year 2025.

What is the revenue of DR. MED. SPIESSENS THOMAS?

As a small company, DR. MED. SPIESSENS THOMAS is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 138,624.

DR. MED. SPIESSENS THOMAS (Private Limited) - Zandhoven

Dossier DR. MED. SPIESSENS THOMAS, printed on 16 September 2026 from databakkes.be/en/0473128386/dr-med-spiessens-thomas. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Not on Peppol Peppol

Not registered in the Peppol network, mandatory for VAT-liable companies since 1 January 2026.

Financials

Financial year 2025

DR. MED. SPIESSENS THOMAS from Zandhoven, company number BE0473128386, closed financial year 2025 with a result of € 102,208 after tax. For that financial year DR. MED. SPIESSENS THOMAS recorded a gross margin of € 138,624 and equity of € 1.3 million. Compared with financial year 2024, the result moved from € 185,361 to € 102,208. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on April 30, 2026.

What it is worth Growing

€ 1.3 million

▲ 8% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 102,208

▼ 45% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 300,289

▼ 47% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 1.3 million.

People and assets in 2025

Vehicles and equipment

€ 110,662

▲ 20% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

€ 1,109

Loans from banks and other lenders, long and short.

Owed to suppliers

€ 69

▼ 99% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 34,592

▲ 21% vs 2024

Taxes, VAT and social contributions still to pay.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 156,200 Gross margin 2022: € 156,200 First fiscal year in the series	€ 187,705 Gross margin 2023: € 187,705 ▲ 20% vs 2022 (€ 156,200) Favourable step	€ 302,589 Gross margin 2024: € 302,589 ▲ 61% vs 2023 (€ 187,705) Favourable step	€ 138,624 Gross margin 2025: € 138,624 ▼ 54% vs 2024 (€ 302,589) Unfavourable step	▼ 54%
Profit after taxes	€ 88,374 Profit after taxes 2022: € 88,374 First fiscal year in the series	€ 106,447 Profit after taxes 2023: € 106,447 ▲ 20% vs 2022 (€ 88,374) Favourable step	€ 185,361 Profit after taxes 2024: € 185,361 ▲ 74% vs 2023 (€ 106,447) Favourable step	€ 102,208 Profit after taxes 2025: € 102,208 ▼ 45% vs 2024 (€ 185,361) Unfavourable step	▼ 45%
Equity	€ 1,075,789 Equity 2022: € 1,075,789 First fiscal year in the series	€ 1,132,237 Equity 2023: € 1,132,237 ▲ 5% vs 2022 (€ 1,075,789) Favourable step	€ 1,236,598 Equity 2024: € 1,236,598 ▲ 9% vs 2023 (€ 1,132,237) Favourable step	€ 1,338,806 Equity 2025: € 1,338,806 ▲ 8% vs 2024 (€ 1,236,598) Favourable step	▲ 8%
Total debts	€ 28,456 Total debts 2022: € 28,456 First fiscal year in the series	€ 41,299 Total debts 2023: € 41,299 ▲ 45% vs 2022 (€ 28,456) Unfavourable step	€ 69,416 Total debts 2024: € 69,416 ▲ 68% vs 2023 (€ 41,299) Unfavourable step	€ 43,263 Total debts 2025: € 43,263 ▼ 38% vs 2024 (€ 69,416) Favourable step	▼ 38%
Cash	€ 126,746 Cash 2022: € 126,746 First fiscal year in the series	€ 356,418 Cash 2023: € 356,418 ▲ 181% vs 2022 (€ 126,746) Favourable step	€ 562,484 Cash 2024: € 562,484 ▲ 58% vs 2023 (€ 356,418) Favourable step	€ 300,289 Cash 2025: € 300,289 ▼ 47% vs 2024 (€ 562,484) Unfavourable step	▼ 47%
Land & buildings	€ 311,870 Land & buildings 2022: € 311,870 First fiscal year in the series	€ 167,400 Land & buildings 2023: € 167,400 ▼ 46% vs 2022 (€ 311,870) Unchanged	€ 2,830 Land & buildings 2024: € 2,830 ▼ 98% vs 2023 (€ 167,400) Unchanged	€ 2,239 Land & buildings 2025: € 2,239 ▼ 21% vs 2024 (€ 2,830) Unchanged	▼ 21%
Retained profit	€ 1,069,589 Retained profit 2022: € 1,069,589 First fiscal year in the series	€ 1,126,037 Retained profit 2023: € 1,126,037 ▲ 5% vs 2022 (€ 1,069,589) Favourable step	€ 1,230,398 Retained profit 2024: € 1,230,398 ▲ 9% vs 2023 (€ 1,126,037) Favourable step	€ 1,332,606 Retained profit 2025: € 1,332,606 ▲ 8% vs 2024 (€ 1,230,398) Favourable step	▲ 8%
Dividend	€ 0 Dividend 2022: € 0 First fiscal year in the series	€ 50,000 Dividend 2023: € 50,000 Unchanged (€ 0) Unchanged	€ 81,000 Dividend 2024: € 81,000 ▲ 62% vs 2023 (€ 50,000) Unchanged	€ 0 Dividend 2025: € 0 ▼ 100% vs 2024 (€ 81,000) Unchanged	▼ 100%
Bank debt	€ 7,571 Bank debt 2022: € 7,571 First fiscal year in the series	€ 7,602 Bank debt 2023: € 7,602 Unchanged (€ 7,571) Unfavourable step	€ 0 Bank debt 2024: € 0 ▼ 100% vs 2023 (€ 7,602) Favourable step	€ 1,109 Bank debt 2025: € 1,109 Unchanged (€ 0) Unfavourable step
Balance sheet total	€ 1,104,245 Balance sheet total 2022: € 1,104,245 First fiscal year in the series	€ 1,173,536 Balance sheet total 2023: € 1,173,536 ▲ 6% vs 2022 (€ 1,104,245) Unchanged	€ 1,306,014 Balance sheet total 2024: € 1,306,014 ▲ 11% vs 2023 (€ 1,173,536) Unchanged	€ 1,382,069 Balance sheet total 2025: € 1,382,069 ▲ 6% vs 2024 (€ 1,306,014) Unchanged	▲ 6%

Key figures of DR. MED. SPIESSENS THOMAS, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 30 April 2027.

What happened to DR. MED. SPIESSENS THOMAS?

What happened at DR. MED. SPIESSENS THOMAS in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Apr 30, 2026 New annual accounts for financial year 2025: profit of € 102,208 (▼ 45% vs 2024). Source: NBB ↗
2000 Thomas Spiessens became a director. NBB
Oct 26, 2000 Start of the company according to the CBE. KBO
Oct 11, 2000 New establishment in Zandhoven. KBO

In short

From € 88,374 profit in 2022 to € 102,208 profit in 2025.

Paid € 220,781 in corporate taxes since 2022.

Best year ever: 2024, with € 185,361 profit.

Paid out € 131,000 in dividends to the owners in total.

Original PDFs at the National Bank ↗

A new publication or filing at DR. MED. SPIESSENS THOMAS? We notify you, reason included.

Follow DR. MED. SPIESSENS THOMAS

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Management

Thomas Spiessens

DR. MED. SPIESSENS THOMAS

Behind DR. MED. SPIESSENS THOMAS is Thomas Spiessens.

See the full network in the app

Directors

According to the 2025 annual accounts

Thomas Spiessens

Director

since 2000

Establishments

Establishment units

Physical locations of this company

Registered office

Dennenlaan 46

2243 Zandhoven

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.

All companies at this address →

DR. F. VANKELECOM

€ 9,715 gross margin · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0473.128.386
VAT number: BE 0473.128.386
Registered office: Dennenlaan 46, 2243 Zandhoven
Names & denominations: DR. MED. SPIESSENS THOMAS
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 26 October 2000
Peppol: Not registered

View on CBE Public ↗ Annual accounts (NBB) ↗